# A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

> **NCT02708095** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 314 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02708095
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-24
- **Primary completion:** 2017-10-12
- **Final completion:** 2017-11-09
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2018-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02708095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02708095, "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02708095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*